Atorvastatin affects atherosclerosis by inhibiting BIP/PERK/eIF2α/CHOP pathway (Song et al., 2011; Jia et al., 2012; Ivanova and Orekhov, 2016). Here, DDIT3 is linked to atherosclerosis.